Heidelberg Edge Perimetry (HEP) Detecting Glaucomatous Visual Field Defects
Launched by WILLS EYE · Aug 17, 2015
Trial Information
Current as of April 28, 2025
Completed
Keywords
ClinConnect Summary
Each participant undergo the following tests:
1. Standard ophthalmic examination (usual care): Best-corrected visual acuity, biomicroscopy (look at front of eye), intraocular pressure (IOP) using Goldman applanation tonometry, central corneal thickness measurement and fundoscopy (look at back of eye).
2. Octopus Visual Field (OVF) Analyzer using G-top strategy recording mean deviation (MD) and pattern standard deviation (PSD).
3. Heidelberg Edge Perimeter (HEP) standard automated perimetry (SAP) using advanced staircase thresholding algorithm (ASTA).
4. Spectralis optical coherence tomogra...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \> 18 years.
- • Best corrected visual acuity of 20/40 or better in the tested eye.
- • Spherical refraction within ±5.0 D, and cylinder correction within ±3.0 D.
- * History of glaucoma, defined as:
- • Characteristic of glaucomatous disc damage: (local narrowing, notching, or absence of the neuroretinal rim in the absence of disc pallor elsewhere).
- Exclusion Criteria:
- • Any condition preventing adequate examination of the pupil or visual field testing (e.g. ptosis, dense corneal opacities or lens opacities);
- • Active infection of the anterior or posterior segments of the eye;
- • Any intraocular surgical or laser procedure within the previous 4 weeks;
- • Participants taking a medication known to affect visual field sensitivity, a coexisting intraocular disease affecting visual field, or a problem other than glaucoma affecting color vision will be excluded.
About Wills Eye
Wills Eye is a leading ophthalmic institution dedicated to advancing the field of eye care through innovative research and clinical trials. With a commitment to improving patient outcomes, Wills Eye collaborates with renowned experts and employs cutting-edge technology to investigate new treatments and therapies for various ocular conditions. Their robust clinical trial program not only enhances the understanding of eye diseases but also aims to bring novel solutions to the forefront of ophthalmology, ensuring that patients have access to the latest advancements in eye health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Leslie J Katz, MD
Principal Investigator
Wills Eye Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials